Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Repeat-dose, Placebo-controlled, Double-blind Study to Evaluate and Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder, When Administered Either in the Morning or in the Evening, in Male and Female Asthmatic Subjects
Brief Summary: This study will be a repeat-dose, double-blind, randomized, placebo controlled, three-way crossover study in patients with persistent bronchial asthma to compare the effect of morning (AM) and evening (PM) dosing with fluticasone furoate (FF)/Vilanterol (VI) inhalation powder on lung function. Following screening there will be a run-in period of 14 days. There will be 3 treatment periods; drug at AM, drug at PM and placebo, which will last for 14 days each with a 14-21 day washout period between starting the next. Key assessments include; forced expiratory volume in one second (FEV1), peak expiratory flow (PEF), vital signs, electrocardiograms (ECGs), adverse event (AE) monitoring and laboratory safety tests.


Options:
A: Arm Label: FF(100mcg)/Vilanterol(25mcg) - AM dosing; Type: EXPERIMENTAL; Interventions: Drug: FF(100mcg)/Vilanterol(25mcg) AM, Drug: Placebo PM | Arm Label: FF(100mcg)/Vilanterol(25mcg) - PM dosing; Type: EXPERIMENTAL; Interventions: Drug: FF(100mcg)/Vilanterol(25mcg) PM, Drug: Placebo AM | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo AM, Drug: Placebo PM | Intervention Type: DRUG; Name: FF(100mcg)/Vilanterol(25mcg) AM; Assigned to Arm(s): FF(100mcg)/Vilanterol(25mcg) - AM dosing | Intervention Type: DRUG; Name: FF(100mcg)/Vilanterol(25mcg) PM; Assigned to Arm(s): FF(100mcg)/Vilanterol(25mcg) - PM dosing | Intervention Type: DRUG; Name: Placebo AM; Assigned to Arm(s): FF(100mcg)/Vilanterol(25mcg) - PM dosing, Placebo | Intervention Type: DRUG; Name: Placebo PM; Assigned to Arm(s): FF(100mcg)/Vilanterol(25mcg) - AM dosing, Placebo
B: Arm Label: GW642444M 25mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Arm Label: GW642444M 50mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Arm Label: GW642444M 100mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Arm Label: GW642444M 200mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Arm Label: GW642444M 400mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Intervention Type: DRUG; Name: GW642444M for 14 days; Assigned to Arm(s): GW642444M 100mcg, GW642444M 200mcg, GW642444M 25mcg, GW642444M 400mcg, GW642444M 50mcg
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: inhaled corticosteroid(ICS)/long acting bronchodilator (LABA); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF/Vilanterol (VI; GW642444M) | Arm Label: ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Furoate | Intervention Type: DRUG; Name: Fluticasone Furoate; Assigned to Arm(s): ICS | Intervention Type: DRUG; Name: FF/Vilanterol (VI; GW642444M); Assigned to Arm(s): inhaled corticosteroid(ICS)/long acting bronchodilator (LABA) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: GW642444M/lactose; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Arm Label: GW642444M/MgSt; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo | Intervention Type: DRUG; Name: GW642444; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo | Intervention Type: DRUG; Name: Magnesium Stearate; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo

Answer: A